Low-dose Decitabine/Cedazuridine Reduces Toxicity While Preserving Efficacy in Low-risk MDS

Low-dose decitabine–cedazuridine shows promising results with the same efficacy as standard dosing but with significantly better safety and tolerability — a potentially new option for patients with low-risk MDS.